Pregnancy Complicated by Cardiac Valvular Disease and Hypertension

To the Editor:
I read with interest the case report and discussion by Dunnick et al,' which appeared in the December 1991 issue of Chest. The authors described the management of a patient with valvular heart disease complicated by pregnancyinduced hypertension. I would like to make several comments.
First, I question the desirability of prolonging a 34-week gestation in a woman with pregnancy-induced hypertension. Clearly, this would not be of any particular benefit to the mother; its only purpose would be to permit further fetal maturation and thus improve neonatal outcome. However, the incidence of respiratory distress syndrome in a Sweek-gestation newborn is as low as 3 percent, and the neonatal mortality is still lower.' Thus, delivery a d d have been accomplished prior to maternal hemodynamic deterioration. Further, there is no need to invoke an "arbitrary time of 35 weeks' gestation"l to terminate the pregnancy; objective evidence of fetal lung mahuity, the primary determinant of neonatal survival, can be reliably obtained through amniocentesis and determination of the lecithin-sphingomyelin ratio.
Second, it is well established that pregnancyinduced hypertension is associated with significant i n t r a v d volume contraction, proportional to the degree of hypertension. Thus, the use of diuretics may be associated with further deterioration. It may be, in fact, that the diuresis performed in this patient led to a decrease in cardiac output, which impaired utemplacental blood flow and led to fetal distress. As Gianopoulos points out in his commentary, placement of a pulmonary artery catheter would have permitted more goal-oriented therapy. ' Finally, it is time to lay to rest the belief that beta-adrenergic blockade during pregnancy can lead to intrauterine growth retardation. In studies of aten~lol,~ oxprenolol,' labetalol? and propranolol,' there is no evidence of any significant effect on fetal growth. Intrauterine growth retardation is far more likely to be due to the underlying m a t e d condition requiring beta-blockade than to the therapy itself. We read with interest the report by O'Riordan and Smaldone,' which appeared in the June 1992 issue of Chest. It was alarming to read that systemic absorption of pentamidine occurred in healthcare workers (HCWs) administering infrequent aerosol pentamidine (AP) treatments (4 to 50 per month? in their institute.
In Toronto we have a centralized communitybased outpatient treatment facility, which has enrolled over 1,200 patients and administered wer 31,000 individual treatments since its opening in Spot urine samples were obtained from each of our HCWs on two separate occasions. Three patients consented to spot urinalysis immediately prior to therapy (positive control), and two health-care control subjects were enrolled (negative control) @ble 1). Samples We consider administration of AP via the Fisoneb system, even in a high-volume clinic such as ours, to have negligible effects on individual HCWs. We agree that low-dose environmental exposure is inevitable, and that occasional higher levels due to environmental spillover should be expected, although they can be minimized. More important, we believe that breath-activated nebulizer systems, such as the Fisoneb system, are preferable because their very design significantly reduces environmental spillage, since they turn off after inspiration ceases or if coughing occurs. 
